This consensus focuses on the transcatheter left atrial appendage closure(LAAC).In response to the growing number of patients with atrial fibrillation,advancements in LA AC technology,and evolving clinical needs,it has been updated by the Structural Heart Disease Professional Committee of the Cardiovascular Physicians Branch of the Chinese Medical Doctor Association.The incidence of atrial fibrillation is increasing with population aging,leading to elevated stroke risk.LAAC offers an effective preventive solution.The consensus provides a detailed overview of LAAC's developmental trajectory,including its pivotal role in the comprehensive management of atrial fibrillation,milestone events in China,and substantial evidence-based data.Regarding team composition,the consensus outlines the inclusion of multidisciplinary professionals with clearly defined roles.It precisely delineates indications as non-valvular atrial fibrillation patients with high stroke risk and qualifying scores in specific scenarios,while also listing contraindications.Methodological aspects are comprehensively addressed,encompassing imaging assessments(such as the roles and key considerations of TTE,TEE,and cardiac CTA),the operational protocols for various devices(the selection,implantation,evaluation,and adjustment for plug-and disc-type devices),and perioperative management.Potential perioperative complications,such as pericardial effusion,stroke,and device dislocation,are reviewed with analyses of their causes and corresponding management strategies.Postoperative antithrombotic treatment strategies are tailored to different stages(intensive,consolidation,and special cases),while detailed follow-up plans(timelines,methods,content,and outcome assessment)are provided.The consensus also explores surgical approach options,highlighting the features and applications of"one-stop"and simplified LAAC procedures.Looking ahead,it focuses on the expansion of the applicable population,technological improvements,device innovations,further advancement of combined treatment,and optimized medication strategies.This comprehensive,precise,and forward-looking guidance aims to enhance LAAC's clinical practice and development,fostering its standardization,precision,and continuous innovation.

In recent years,the number of Chest Pain Centers in China has increased rapidly.As of December 2024,there were 5 947 registered units of Chest Pain Centers nationwide,2 994 of which had passed the acceptance.As of April 2025,18.34 million acute chest pain cases have been treated at Chest Pain Centers nationwide,according to the Chest Pain Center reporting platform.The Chest Pain Centers treated more than 3.62 million patients with acute chest pain in 2024,including more than 770 000 patients with acute myocardial infarction,and achieved positive results:significantly increasing the proportion of reperfusion therapy for acute ST-segment elevation myocardial infarction patients,ensuring the treatment of myocardial infarction patients in a short time,shortening the length of patient hospitalization,and reducing the hospitalization costs and mortality of patients.Through the construction of Chest Pain Center,the treatment process was significantly optimized and the prognosis of patients was improved.At present,the construction and quality control of Chest Pain Centers still need to be further promoted.In some areas,the construction proportion of Chest Pain Centers and the level of diagnosis and treatment of chest pain need to be improved,patient delay is still an important challenge for the treatment of acute chest pain in China.

To improve the diagnosis,treatment,and management of panvascular diseases,under the guidance of the National Clinical Research Center for Interventional Medicine,the Panvascular Medicine Expert Committee established a standardized registry database for panvascular diseases and encouraged all Panvascular Disease Management Centers(PVMCs)to submit case data.By the end of 2024,a total of 143 640 case records had been submitted by PVMCs.This report systematically evaluates the data quality of the database.The results show that the overall average completeness rate of mandatory fields was 79.23％.Among the patients,56.13％were male,with an average age of 60.71 years.The major cardiovascular risk factors included hypertension(36.96％),dyslipidemia(28.86％),diabetes(17.67％)and smoking(17.40％).Regarding medication use,statins had the highest utilization rate(95.86％).When analyzed by drug category-antiplatelet,anticoagulant,glucose-lowering,and antihypertensive medications-aspirin(85.71％),rivaroxaban(72.91％),sodium-glucose co-transporter 2 inhibitors(45.58％),and beta-blockers(50.01％)were the most frequently used in their respective groups.In the atherosclerotic cardiovascular disease(ASCVD)risk assessment,the proportions of high-risk,very high-risk,and extremely high-risk patients were 11.98％,14.57％,and 10.45％,respectively.At the 12-month follow-up after registration,the average total cholesterol level showed a significant decrease[(3.51±0.88)mmol/L vs.(4.82±1.21)mmol/L],while the average systolic blood pressure exhibited an increasing trend[(140.7±24.2)mmHg vs.(135.2±17.12)mmHg].As the first standardized,cross-disciplinary,multi-center collaborative database in China,it integrates multidimensional data,including risk factors,vascular lesion characteristics,and disease diagnosis and treatment measures.It covers the full spectrum of patients,from early high-risk populations to advanced ASCVD cases,with an emphasis on collecting imaging and biomarker data and tracking long-term clinical outcomes.We believe this database will provide high-quality data for precise risk stratification,optimized treatment,and real-world research in panvascular diseases.Through continuous upgrades of the information system and improvements in the quality control framework,the accuracy,completeness,and usability of the database have been further enhanced,contributing to the achievement of the"Healthy China"initiative's goal of reducing cardiovascular events.

Percutaneous renal denervation(RDN)is a minimally invasive interventional treatment for hypertension that has been used in clinics at home and abroad,primarily for patients with resistant hypertension or who cannot tolerate antihypertensive drugs.Current clinical studies have confirmed the safety and efficacy of this technique.As RDN is still in its promotional and popularization stage,the expert group has written this clinical pathway to promote the orderly implementation of this technology,standardize the operating process,and standardize diagnostic and therapeutic behaviors.The pathway describes the clinical assessment of patients in detail(including indications,contraindications,and the patient screening process),the standardized operating process for RDN(including perioperative medication,anaesthesia,ablation,and management of complications),and the postoperative follow-up plan(including follow-up content,methods,and timing).It is hoped that this will serve as a reference for physicians involved in RDN clinical work,standardize diagnostic and therapeutic behaviors,and promote the standardized,precise,and sustainable development of the RDN discipline.

In recent years,the number of Chest Pain Centers in China has increased rapidly.As of December 2024,there were 5 947 registered units of Chest Pain Centers nationwide,2 994 of which had passed the acceptance.As of April 2025,18.34 million acute chest pain cases have been treated at Chest Pain Centers nationwide,according to the Chest Pain Center reporting platform.The Chest Pain Centers treated more than 3.62 million patients with acute chest pain in 2024,including more than 770 000 patients with acute myocardial infarction,and achieved positive results:significantly increasing the proportion of reperfusion therapy for acute ST-segment elevation myocardial infarction patients,ensuring the treatment of myocardial infarction patients in a short time,shortening the length of patient hospitalization,and reducing the hospitalization costs and mortality of patients.Through the construction of Chest Pain Center,the treatment process was significantly optimized and the prognosis of patients was improved.At present,the construction and quality control of Chest Pain Centers still need to be further promoted.In some areas,the construction proportion of Chest Pain Centers and the level of diagnosis and treatment of chest pain need to be improved,patient delay is still an important challenge for the treatment of acute chest pain in China.

To improve the diagnosis,treatment,and management of panvascular diseases,under the guidance of the National Clinical Research Center for Interventional Medicine,the Panvascular Medicine Expert Committee established a standardized registry database for panvascular diseases and encouraged all Panvascular Disease Management Centers(PVMCs)to submit case data.By the end of 2024,a total of 143 640 case records had been submitted by PVMCs.This report systematically evaluates the data quality of the database.The results show that the overall average completeness rate of mandatory fields was 79.23％.Among the patients,56.13％were male,with an average age of 60.71 years.The major cardiovascular risk factors included hypertension(36.96％),dyslipidemia(28.86％),diabetes(17.67％)and smoking(17.40％).Regarding medication use,statins had the highest utilization rate(95.86％).When analyzed by drug category-antiplatelet,anticoagulant,glucose-lowering,and antihypertensive medications-aspirin(85.71％),rivaroxaban(72.91％),sodium-glucose co-transporter 2 inhibitors(45.58％),and beta-blockers(50.01％)were the most frequently used in their respective groups.In the atherosclerotic cardiovascular disease(ASCVD)risk assessment,the proportions of high-risk,very high-risk,and extremely high-risk patients were 11.98％,14.57％,and 10.45％,respectively.At the 12-month follow-up after registration,the average total cholesterol level showed a significant decrease[(3.51±0.88)mmol/L vs.(4.82±1.21)mmol/L],while the average systolic blood pressure exhibited an increasing trend[(140.7±24.2)mmHg vs.(135.2±17.12)mmHg].As the first standardized,cross-disciplinary,multi-center collaborative database in China,it integrates multidimensional data,including risk factors,vascular lesion characteristics,and disease diagnosis and treatment measures.It covers the full spectrum of patients,from early high-risk populations to advanced ASCVD cases,with an emphasis on collecting imaging and biomarker data and tracking long-term clinical outcomes.We believe this database will provide high-quality data for precise risk stratification,optimized treatment,and real-world research in panvascular diseases.Through continuous upgrades of the information system and improvements in the quality control framework,the accuracy,completeness,and usability of the database have been further enhanced,contributing to the achievement of the"Healthy China"initiative's goal of reducing cardiovascular events.

Percutaneous renal denervation(RDN)is a minimally invasive interventional treatment for hypertension that has been used in clinics at home and abroad,primarily for patients with resistant hypertension or who cannot tolerate antihypertensive drugs.Current clinical studies have confirmed the safety and efficacy of this technique.As RDN is still in its promotional and popularization stage,the expert group has written this clinical pathway to promote the orderly implementation of this technology,standardize the operating process,and standardize diagnostic and therapeutic behaviors.The pathway describes the clinical assessment of patients in detail(including indications,contraindications,and the patient screening process),the standardized operating process for RDN(including perioperative medication,anaesthesia,ablation,and management of complications),and the postoperative follow-up plan(including follow-up content,methods,and timing).It is hoped that this will serve as a reference for physicians involved in RDN clinical work,standardize diagnostic and therapeutic behaviors,and promote the standardized,precise,and sustainable development of the RDN discipline.

This consensus focuses on the transcatheter left atrial appendage closure(LAAC).In response to the growing number of patients with atrial fibrillation,advancements in LA AC technology,and evolving clinical needs,it has been updated by the Structural Heart Disease Professional Committee of the Cardiovascular Physicians Branch of the Chinese Medical Doctor Association.The incidence of atrial fibrillation is increasing with population aging,leading to elevated stroke risk.LAAC offers an effective preventive solution.The consensus provides a detailed overview of LAAC's developmental trajectory,including its pivotal role in the comprehensive management of atrial fibrillation,milestone events in China,and substantial evidence-based data.Regarding team composition,the consensus outlines the inclusion of multidisciplinary professionals with clearly defined roles.It precisely delineates indications as non-valvular atrial fibrillation patients with high stroke risk and qualifying scores in specific scenarios,while also listing contraindications.Methodological aspects are comprehensively addressed,encompassing imaging assessments(such as the roles and key considerations of TTE,TEE,and cardiac CTA),the operational protocols for various devices(the selection,implantation,evaluation,and adjustment for plug-and disc-type devices),and perioperative management.Potential perioperative complications,such as pericardial effusion,stroke,and device dislocation,are reviewed with analyses of their causes and corresponding management strategies.Postoperative antithrombotic treatment strategies are tailored to different stages(intensive,consolidation,and special cases),while detailed follow-up plans(timelines,methods,content,and outcome assessment)are provided.The consensus also explores surgical approach options,highlighting the features and applications of"one-stop"and simplified LAAC procedures.Looking ahead,it focuses on the expansion of the applicable population,technological improvements,device innovations,further advancement of combined treatment,and optimized medication strategies.This comprehensive,precise,and forward-looking guidance aims to enhance LAAC's clinical practice and development,fostering its standardization,precision,and continuous innovation.

Tricuspid regurgitation(TR)is a common heart valve disease traditionally treated with surgery,which is invasive and high-risk.Recently,transcatheter tricuspid valve intervention(TTVI)technology has achieved major breakthroughs.It is being promoted internationally and several expert consensus documents have been launched abroad.However,in China,there is still a lack of consensus documents in this regard.In order to promote the safe,standardized and healthy development of this technology,this expert consensus is specially compiled.This consensus will introduce anatomy,epidemiology,classification and pathogenesis of TR,the traditional treatment and TTVI,preoperative evaluation and clinical efficacy endpoints.We sort out ten core viewpoints so that readers can quickly grasp the essence of the consensus.

In recent years,the number of Chest Pain Centers in China has increased rapidly.As of December 2023,there were 5 725 registered units of Chest Pain Centers nationwide,2 660 of which had passed the acceptance,and a total of 14.67 million patients with acute chest pain were treated.The Chest Pain Centers treated more than 3.18 million patients with acute chest pain in 2023,including more than 690 000 patients with acute myocardial infarction,and achieved positive results:significantly increasing the proportion of reperfusion therapy for ST-segment elevation myocardial infarction patients,ensuring the treatment of myocardial infarction patients in a short time,shortening the length of patient hospitalization,and reducing the hospitalization costs and mortality of patients.Through the construction of chest pain center,the treatment process was significantly optimized and the prognosis of patients was improved.At present,the construction and quality control of Chest Pain Centers still need to be further promoted.In some areas,the construction proportion of Chest Pain Centers and the level of diagnosis and treatment of chest pain need to be improved,patient delay is still an important challenge for the treatment of acute chest pain in China.